Le Lézard
Classified in: Health, Science and technology
Subject: CONFERENCE CALLS

VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017


CAMPBELL, CA--(Marketwired - October 31, 2017) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2017 after the market close on Tuesday, November 7, 2017. The company will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT the same day to review results and provide a business update.

To listen via webcast, please visit http://ir.vivus.com/, or by clicking here.

To listen via phone, please use the dial in information provided below.

Dial in Details:
Toll-Free: (877) 359-2916
International: (224) 357-2386
Passcode: 7997677

A webcast replay will be available on the VIVUS website for 30 days.

About VIVUS
VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs in human health. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2016 as filed on March 8, 2017, and as amended by the Form 10-K/A filed on April 26, 2017, and periodic reports filed with the Securities and Exchange Commission.


These press releases may also interest you

at 19:35
CV Sciences, Inc.  (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it has consummated...

at 19:32
Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy...

at 19:21
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug...

at 18:30
Cannabix Technologies Inc. (the "Company or Cannabix") reports that it has entered into an arm's length marketing agreements with the following parties: Effective May 13, 2024, the Company has engaged Financial Buzz Media Networks LLC ("FBMN") for...

at 18:25
It is with great pleasure that we announce the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks...

at 18:03
Kelyniam Global , a maker of custom cranial implants, today announced results for its quarter ended March 31, 2024.  Financial highlights for the three months ended March 31, 2024 and the same period in 2023 include:  Total revenue of $957,447...



News published on and distributed by: